Synthetic Biologics Stock Price, News & Analysis (NYSEAMERICAN:SYN)

$0.68 0.00 (-0.59 %)
(As of 11/18/2017 01:53 AM ET)
Previous Close$0.68
Today's Range$0.64 - $0.68
52-Week Range$0.41 - $1.05
Volume1.01 million shs
Average Volume875,586 shs
Market Capitalization$86.44 million
P/E RatioN/A
Dividend YieldN/A

About Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics logoSynthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).

Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • CUSIP: N/A
  • Web:
  • Trailing EPS: ($0.22)
  • Return on Equity: -461.33%
  • Return on Assets: -103.45%
  • Outstanding Shares: 128,570,000

Frequently Asked Questions for Synthetic Biologics (NYSEAMERICAN:SYN)

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics Inc (NYSEAMERICAN:SYN) posted its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.10. View Synthetic Biologics' Earnings History.

Where is Synthetic Biologics' stock going? Where will Synthetic Biologics' stock price be in 2017?

4 Wall Street analysts have issued twelve-month target prices for Synthetic Biologics' stock. Their predictions range from $5.00 to $6.00. On average, they anticipate Synthetic Biologics' share price to reach $5.50 in the next year. View Analyst Ratings for Synthetic Biologics.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 7,176,264 shares, an increase of 3.9% from the October 13th total of 6,905,995 shares. Based on an average daily trading volume, of 880,277 shares, the short-interest ratio is presently 8.2 days. Currently, 6.3% of the shares of the company are sold short.

Who are some of Synthetic Biologics' key competitors?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the folowing people:

  • Jeffrey Lucero Riley, President, Chief Executive Officer, Director (Age 46)
  • Steven A. Shallcross, Chief Financial Officer, Treasurer, Secretary (Age 52)
  • Joseph A. Sliman, Chief Medical Officer (Age 44)
  • Jeffrey J. Kraws, Non-Executive Independent Chairman of the Board (Age 53)
  • Scott L. Tarriff, Independent Director (Age 57)
  • Jeffrey Alan Wolf J.D., Independent Director (Age 53)

How do I buy Synthetic Biologics stock?

Shares of Synthetic Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of Synthetic Biologics stock can currently be purchased for approximately $0.68.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $86.44 million.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.

MarketBeat Community Rating for Synthetic Biologics (NYSEAMERICAN SYN)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  259
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Synthetic Biologics (NYSEAMERICAN:SYN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $5.50

Consensus Price Target History for Synthetic Biologics (NYSEAMERICAN:SYN)

Price Target History for Synthetic Biologics (NYSEAMERICAN:SYN)

Analysts' Ratings History for Synthetic Biologics (NYSEAMERICAN:SYN)

DateFirmActionRatingPrice TargetDetails
5/22/2017William BlairReiterated RatingOutperform$5.00View Rating Details
1/14/2017FBR & CoReiterated RatingOverweight$6.00View Rating Details
11/25/2016LaurentianDowngradeBuy -> Speculative BuyView Rating Details
11/25/2016Laurentian Bank of CanadaDowngradeBuy -> Speculative BuyView Rating Details
8/31/2016Griffin SecuritiesSet Price TargetBuy$9.00 -> $5.80View Rating Details
8/25/2016BTIG ResearchInitiated CoverageBuy$5.00View Rating Details
2/5/2016Royal Bank Of CanadaReiterated RatingOutperform$8.00View Rating Details
1/4/2016Telsey Advisory GroupInitiated CoverageOutperformView Rating Details
(Data available from 11/19/2015 forward)


Earnings History and Estimates Chart for Synthetic Biologics (NYSEAMERICAN:SYN)

Earnings by Quarter for Synthetic Biologics (NYSEAMERICAN:SYN)

Earnings History by Quarter for Synthetic Biologics (NYSEAMERICAN SYN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($0.04)($0.14)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.06)($0.03)ViewListenView Earnings Details
5/4/2017Q1 2017($0.07)($0.02)ViewListenView Earnings Details
3/2/2017Q4 2016($0.08)($0.02)ViewListenView Earnings Details
11/1/2016Q316($0.10)($0.09)ViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.12)ViewN/AView Earnings Details
3/10/2016Q415($0.12)($0.12)ViewListenView Earnings Details
11/5/2015Q315($0.12)($0.12)ViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.19)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.11)ViewListenView Earnings Details
3/16/2015($0.06)($0.09)ViewN/AView Earnings Details
11/14/2014Q314($0.05)($0.08)ViewN/AView Earnings Details
8/14/2014($0.06)($0.08)ViewN/AView Earnings Details
5/15/2014Q1 14($0.08)($0.07)ViewN/AView Earnings Details
3/31/2014($0.06)($0.09)ViewN/AView Earnings Details
11/14/2013Q3($0.06)($0.08)ViewListenView Earnings Details
8/14/2013Q2 2013($0.06)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Synthetic Biologics (NYSEAMERICAN:SYN)

No earnings estimates for this company have been tracked by


Dividend History for Synthetic Biologics (NYSEAMERICAN:SYN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Synthetic Biologics (NYSEAMERICAN SYN)

Insider Trades by Quarter for Synthetic Biologics (NYSEAMERICAN:SYN)

Insider Trades by Quarter for Synthetic Biologics (NYSEAMERICAN SYN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/17/2015Brendan CannonDirectorBuy5,000$0.39$1,925.00
11/30/2015Christoper MartinDirectorBuy80,000$0.40$32,000.00
11/27/2015Bartley Vaden HeathDirectorBuy35,000$0.28$9,800.00
9/2/2015Randal J KirkMajor ShareholderBuy937,500$3.20$3,000,000.00View SEC Filing  
5/22/2014Charles Evan BallantyneCFOBuy10,000$1.35$13,500.00View SEC Filing  
4/29/2014Steve H KanzerDirectorSell263,112$2.90$763,024.80View SEC Filing  
12/17/2013Randal J KirkMajor ShareholderBuy2,500,000$1.00$2,500,000.00View SEC Filing  
1/7/2013Jeffrey Scott RileyCEOBuy2,900$0.17$493.00View SEC Filing  
1/3/2013Jeffrey Scott RileyCEOBuy2,000$1.71$3,420.00View SEC Filing  
10/29/2012Randal J KirkMajor ShareholderBuy3,125,000$1.60$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Synthetic Biologics (NYSEAMERICAN SYN)

Synthetic Biologics Inc (SYN) Short Interest UpdateSynthetic Biologics Inc (SYN) Short Interest Update - November 13 at 11:34 PM

Social Media

Social activity is not available for this stock.



Synthetic Biologics (NYSEAMERICAN SYN) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.